Protective Effects of 20(S)-Protopanaxtriol on Viral Myocarditis Infected by Coxsackievirus B3 | Zendy

Xiaoyan Wang | Zendy; Ya-Feng Wang | Zendy; Zhe Ren | Zendy; Chuiwen Qian | Zendy; Yicheng Li | Zendy; Qingduan Wang | Zendy; Yan Zhang | Zendy; Liyun Zheng | Zendy; Jinhua Jiang | Zendy; ChongRen Yang | Zendy; Dong Wang | Zendy; YingJun Zhang | Zendy; Jianglin Fan | Zendy; Yifei Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Protective Effects of 20(S)-Protopanaxtriol on Viral Myocarditis Infected by Coxsackievirus B3

Author(s) -

Xiaoyan Wang,

Ya-Feng Wang,

Zhe Ren,

Chuiwen Qian,

Yicheng Li,

Qingduan Wang,

Yan Zhang,

Liyun Zheng,

Jinhua Jiang,

ChongRen Yang,

Dong Wang,

YingJun Zhang,

Jianglin Fan,

Yifei Wang

Publication year - 2012

Publication title -

pathobiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.941

H-Index - 53

eISSN - 1423-0291

pISSN - 1015-2008

DOI - 10.1159/000331229

Subject(s) - coxsackievirus , myocarditis , viral myocarditis , virology , enterovirus , medicine , immunology , biology , virus

Coxsackievirus B3 (CVB3) is a dominant causative agent for viral myocarditis. So far, effective therapies for the treatment of the disease are not available. 20(S)-Protopanaxtriol is a major component of Panax pseudoginseng and has been clinically used for the treatment of heart diseases. However, it is not known whether 20(S)-protopanaxtriol exerts any anti-viral effects. Thus, the aim of this study was to investigate the therapeutic effects of 20(S)-protopanaxtriol against CVB3 in vivo and in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research